Opendata, web and dolomites

EpiPredict SIGNED

Epigenetic regulation of endocrine therapy resistance in breast cancer: A systems medicine approach to predict treatment outcome

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EpiPredict project word cloud

Explore the words cloud of the EpiPredict project. It provides you a very rough idea of what is the project "EpiPredict" about.

academia    computation    iterative    mission    translational    beneficiaries    public    boost    patient    biotech    succeed    clinical    underlying    systematic    receptor    private    visiting    monitoring    narrowly    pharma    setting    positive    pharmaceutical    industry    diagnostic    epigenetic    technologies    tools    scientists    esrs    academic    tamoxifen    outcome    environments    personalized    ict    science    supradisciplinary    consideration    intersectorial    whilst    train    breast    trained    protein    generation    combining    urgent    entrepreneurial    impulses    parties    socio    ensures    ample    mindset    interference    computational    profiling    extra    job    cancer    diseases    fellows    stage    treatment    prevention    achievements    involvement    estrogen    12    medical    medicine    markers    epipredict    central    successfully    innovative    gene    young    considering    exposure    industrial    employs    training    compete    cohort    leaders    ranging    careers    frequent    epigenetics    personal    experts    resistance    equipped    drive    predict    interacting    reversal    er    multidisciplinary    scene   

Project "EpiPredict" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITEIT VAN AMSTERDAM 

Organization address
address: SPUI 21
city: AMSTERDAM
postcode: 1012WX
website: www.uva.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://redict.eu
 Total cost 2˙797˙697 €
 EC max contribution 2˙797˙697 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2014
 Funding Scheme MSCA-ITN-ETN
 Starting year 2015
 Duration (year-month-day) from 2015-01-01   to  2018-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITEIT VAN AMSTERDAM NL (AMSTERDAM) coordinator 766˙122.00
2    IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE UK (LONDON) participant 546˙575.00
3    DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG DE (HEIDELBERG) participant 498˙432.00
4    UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA IT (MILANO) participant 258˙061.00
5    ACADEMISCH ZIEKENHUIS GRONINGEN NL (GRONINGEN) participant 255˙374.00
6    Epiontis GmbH DE (Berlin) participant 249˙216.00
7    SZEGEDI BIOLOGIAI KUTATOKOZPONT HU (SZEGED) participant 223˙913.00
8    CLINICAGENO LIMITED UK (COULSDON SURREY) participant 0.00
9    AHT Management Kft HU (Budapest) partner 0.00
10    Biotecture Ltd NL (Amsterdam) partner 0.00
11    EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH CH (ZUERICH) partner 0.00
12    FH JOANNEUM GESELLSCHAFT MBH AT (GRAZ) partner 0.00
13    Rathenau Instituut NL (Amsterdam) partner 0.00
14    STIFTELSEN FRAUNHOFER-CHALMERS CENTRUM FOR INDUSTRIMATEMATIK SE (GOETEBORG) partner 0.00
15    Synvolux Therapeutics BV NL (Leiden) partner 0.00

Map

 Project objective

The mission of EpiPredict is to train a multidisciplinary cohort of young researchers in a new approach to fully exploit the epigenetics of complex diseases. The 12 early-stage researchers (ESRs) will focus on a narrowly defined case, Tamoxifen-induced resistance in Estrogen Receptor positive (ER) breast cancer, considering five resistance interacting pathways. Given the frequent Tamoxifen treatment failure, resistance prevention and reversal is an urgent clinical problem that is central in EpiPredict. The EpiPredict intersectorial training programme employs a timely systems medicine approach combining next-generation systematic epigenetic, gene/protein profiling with innovative gene-specific epigenetic interference technologies for iterative computational modelling. Together the ESRs will identify key epigenetic changes underlying Tamoxifen induced resistance. This will provide an important step towards diagnostic markers/tools to predict treatment outcome and response monitoring setting the scene for breast cancer personalized medicine. The fellows will be trained by experts from 6 academic and 2 non-academic beneficiaries and 7 partner organizations (1 academic, 6 non-academic including industrial/socio-public parties) and 5 visiting scientists, from fields ranging from epigenetics to both computation and medicine. Strong involvement of the private sector ensures exploitation of EpiPredict achievements and exposure of the ESRs to an entrepreneurial mindset. The cohort of supradisciplinary researchers represents a new generation of research leaders equipped to address complex diseases whilst taking personalized patient aspects into consideration. They will be equipped to compete successfully and succeed in their personal careers. EpiPredict will boost academia and pharma/biotech environments, providing extra impulses to drive European translational science, systems medicine, pharmaceutical industry, and Medical ICT offering ample job opportunities.

 Deliverables

List of deliverables.
Prizes second annual meeting Other 2019-07-10 14:48:58
PhD degrees Other 2019-07-10 14:48:58
Prizes fourth annual meeting Other 2019-07-10 14:48:58
Prizes third annual meeting Other 2019-07-10 14:48:58
Prize first annual meeting Other 2019-07-10 14:48:57

Take a look to the deliverables list in detail:  detailed list of EpiPredict deliverables.

 Publications

year authors and title journal last update
List of publications.
2018 Özge Saatci, Simone Borgoni, Özge Akbulut, Selvi Durmuş, Umar Raza, Erol Eyüpoğlu, Can Alkan, Aytekin Akyol, Özgür Kütük, Stefan Wiemann, Özgür Şahin
Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer
published pages: 2251-2269, ISSN: 0950-9232, DOI: 10.1038/s41388-017-0108-9
Oncogene 37/17 2019-07-10
2017 D Goubert, W F Beckman, P J Verschure, M G Rots
Epigenetic editing: towards realization of the curable genome concept
published pages: 13006, ISSN: 2057-1739, DOI: 10.1088/2057-1739/aa5cc0
Convergent Science Physical Oncology 3/1 2019-07-10
2018 Thierry D.G.A. Mondeel, Stefania Astrologo, Yanfei Zhang, Hans V. Westerhoff
NET works after all? Engineering robustness through diversity
published pages: 128-137, ISSN: 2405-8963, DOI: 10.1016/j.ifacol.2018.09.007
IFAC-PapersOnLine 51/19 2019-07-10
2016 Juan Song, David Cano Rodriguez, Melanie Winkle, Rutger A.F. Gjaltema, Désirée Goubert, Tomasz P. Jurkowski, Irene H Heijink, Marianne G. Rots, Machteld N Hylkema
Targeted epigenetic editing of SPDEF reduces mucus production in lung epithelial cells
published pages: ajplung.00059.20, ISSN: 1040-0605, DOI: 10.1152/ajplung.00059.2016
American Journal of Physiology - Lung Cellular and Molecular Physiology 2019-07-10
2017 Luca Magnani, Gianmaria Frigè, Raffaella Maria Gadaleta, Giacomo Corleone, Sonia Fabris, Hermannus Kempe, Pernette J Verschure, Iros Barozzi, Valentina Vircillo, Sung-Pil Hong, Ylenia Perone, Massimo Saini, Andreas Trumpp, Giuseppe Viale, Antonino Neri, Simak Ali, Marco Angelo Colleoni, Giancarlo Pruneri, Saverio Minucci
Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer
published pages: 444-450, ISSN: 1061-4036, DOI: 10.1038/ng.3773
Nature Genetics 49/3 2019-07-10

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EPIPREDICT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EPIPREDICT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

BIGMATH (2018)

Big Data Challenges for Mathematics

Read More  

DISTINCT (2019)

Dementia: Intersectorial Strategy for Training and Innovation Network for Current Technology (DISTINCT)

Read More  

POLISS (2019)

Policies for Smart Specialisation

Read More